Here are five things to know:
1. The price hike involves nitrofurantoin, an antibiotic used to treat bladder infections. It was first marketed in 1953 and is listed on the World Health Organization’s list of essential medicines.
2. The price of a bottle of the antibiotic was raised in August from $474.75 to $2,392.
3. In an interview, Nostrum’s CEO Nirmal Mulye defended the sharp price hike. He said, according to the Financial Times, that he priced the product according to market dynamics, adding that it is “a moral requirement to make money when you can … to sell the product for the highest price.”
4. Mr. Mulye said his company was responding to a price hike from the maker of the branded version of nitrofurantoin, Casper Pharma. The brand name drugmaker increased the price of its product by 182 percent between 2015 and March 2018. The brand-name version, called Furadantin, costs $2,800.
5. “The point here is the only other choice is the brand at the higher price. It is still a saving regardless of whether it is a big one or not,” Mr. Mulye told the Financial Times.
Read the full story here.
More articles on pharmacy:
Hospitals mark up drugs by 479%: 6 report findings
6 latest drug, medical device recalls
7 things to know about insulin cost hikes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.